Unusual hypersensitivity to warfarin in a critically ill patient
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
A patient was admitted to the intensive care unit because of respiratory failure, and warfarin therapy was started at 2 mg/day for the treatment of pulmonary embolism, together with other medications. Despite the low dosage of warfarin, international normalized ratio (INR) was markedly elevated from 1.15 to 11.28 for only 4 days, and bleeding symptoms concurrently developed. Vitamin K2 was infused along with discontinuation of warfarin. One day later, the INR was found to have decreased, and bleeding was also improved. An objective causality assessment indicated a probable relationship between clotting abnormality and warfarin administration, although the degree of elevation of the INR was unusual in the light of the daily warfarin dose and duration of its exposure. Based on the clinical status of the patient, it was suspected that several conditions contributed to the abnormal hypersensitivity to warfarin. Contributory factors probably included pharmacokinetic interactions with co-administrated drugs, vitamin K deficiency caused by decreased dietary intake, reduced gut bacterial production, impaired intestinal absorption and hepatic synthetic capacity, and increased consumption of clotting factors. In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid fatal haemorrhage after initiating warfarin therapy regardless of the dosage.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Unusual hypersensitivity to warfarin in a critically ill patient
- Date Crossref
- 01/10/2004
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Shiga University of Medical Science Hospital Department of Hospital Pharmacy pays non établi dans la noticeÉtablissement de santé
-
Shiga University of Medical Science pays non établi dans la noticeUniversité ou école supérieure
-
Department of Hospital Pharmacy pays non établi dans la noticeÉtablissement de santé
Department of Hospital Pharmacy — Shiga University of Medical Science Hospital, Shiga University of Medical Science et Department of Hospital Pharmacy.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.